Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1 antibody) combined with chemotherapy, then guided by PET-CT assessment to change the following chemoradiotherapy regiment for locally advanced unresectable ESCC.
Esophageal Squamous Cell Carcinoma
DRUG: Adebrelimab+TP/FP+ radiation therapy|DRUG: Adebrelimab+FP/TP+ radiation therapy
Progression free survival (PFS), Baseline to measured date of progression or death from any cause, evaluated in 24 months since the treatment began
1. Objective response rate (ORR), Baseline to measured stable disease, tumor assessment every 6 weeks since the treatment began，up to 24 monthss|2. Duration of Overall Response（DoR）, The duration of overall response is measured from the time that measurement criteria are met for complete response or partial response until the first date that recurrent or progressive disease is objectively documented., tumor assessment every 6 weeks since the treatment began，up to 24 months|3. Overall survival (OS), Baseline to measured date of death from any cause, the first day of treatment to death or last survival confirm date,up to 24 months|4. Adverse events, Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. The number of Participants with adverse events will be recorded at each treatment visit., up to 24 months
This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1 antibody) combined with chemotherapy, then guided by PET-CT assessment to change the following chemoradiotherapy regiment for locally advanced unresectable ESCC.